Vical A phase III study of Vical's melanoma immunotherapy allovectin-7 will have results ready in August, the company said recently. The survey says: 34 percent of respondents are predicting a positive result from the allovectin-7 melanoma study. A plurality of respondents -- 45 percent -- call the study a failure; while 23 percent chose not to make a prediction. I'm also predicting failure for allovectin-7 and discussed my reasons to be bearish in a column published in May. Here are the results in pie-chart form: My panel of 12 professional healthcare investors is even more negative on Vical, with 11, or 93 percent, predicting the allovectin-7 study will fail. One investor chose not to make a prediction. None forecast positive results. Until the past week or so, Vical has not acted like a stock with positive trial results looming. VICL data by YCharts In the past two months, Vical's short interest has increased 32 percent and currently stands at 12.7 million shares.